Australian biotech market watch 22/07/09
22 July, 2009 by Tim DeanCochlear, Fisher & Paykel, Ramsay, ResMed, Sigma, Sonic Health Care, Primary Health Care
Life and death of a white blood cell
21 July, 2009 by Staff WritersCell division find prompts overhaul of immune response modelling.
ChemGenex appoints new CCO
20 July, 2009 by Tim DeanNew chief commercial officer and senior vice president appointed ahead of omacetaxine launch in 2010.
Australian biotech market watch 17/07/09
17 July, 2009 by Tim DeanAnsell, Cochlear, OMI, CSL, Ramsay, Sonic Health Care, Cellestis, Sirtex
New study offers hope for dyspeptic horses
16 July, 2009 by Staff WritersBioProspect initiates study of Bioeffective A to treat common gastric problem in horses.
Glowing Phase II results for Clinuvel
15 July, 2009 by Tim DeanClinuvel announces positive results in Phase II Solar Urticaria study.
Victorian innovation funding round kicks off
10 July, 2009 by Staff WritersJoint Victoria-Israel Science and Technology R&D Fund, VISTECH, funding round opens.
Australian biotech market watch 03/07/09
03 July, 2009 by Tim DeanCochlear, Healthscope, Blackmores, Ramsey, CSL, ResMed
Australian biotech market watch 01/07/09
01 July, 2009 by Tim DeanCochlear, Ramsay, ResMed, Biota, Ansell
Improving medical device development
01 July, 2009 by Staff WritersNew model aims to streamline medical device development and aid in gaining regulatory approval.
Australian biotech market watch 26/06/09
26 June, 2009 by Tim DeanResMed, CSL, Biota, Sonic Healthcare, ChemGenex, Sirtex
Bionomics commences clinical trial
25 June, 2009 by Tim DeanAnti-anxiety drug, BNC210, to undergo phase I clinical trial in Adelaide.
Phosphagenics signs agreement with CSL
22 June, 2009 by Staff WritersCSL to evaluate Phosphagenics' TMP technology with the possibility of an expanded collaboration in the future.
